- Home
- TAC vs SRRK Comparison
TAC vs SRRK Comparison
Compare TAC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- SRRK
- Stock Information
- Founded
- TAC 1909
- SRRK 2012
- Country
- TAC Canada
- SRRK United States
- Employees
- TAC N/A
- SRRK N/A
- Industry
- TAC Electric Utilities: Central
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAC Utilities
- SRRK Health Care
- Exchange
- TAC Nasdaq
- SRRK Nasdaq
- Market Cap
- TAC 3.1B
- SRRK 2.8B
- IPO Year
- TAC N/A
- SRRK 2018
- Fundamental
- Price
- TAC $10.76
- SRRK $29.92
- Analyst Decision
- TAC
- SRRK Strong Buy
- Analyst Count
- TAC 0
- SRRK 7
- Target Price
- TAC N/A
- SRRK $34.00
- AVG Volume (30 Days)
- TAC 968.5K
- SRRK 921.6K
- Earning Date
- TAC 11-05-2024
- SRRK 11-12-2024
- Dividend Yield
- TAC 1.61%
- SRRK N/A
- EPS Growth
- TAC N/A
- SRRK N/A
- EPS
- TAC 0.38
- SRRK N/A
- Revenue
- TAC $2,065,953,587.00
- SRRK N/A
- Revenue This Year
- TAC N/A
- SRRK N/A
- Revenue Next Year
- TAC N/A
- SRRK N/A
- P/E Ratio
- TAC $27.40
- SRRK N/A
- Revenue Growth
- TAC N/A
- SRRK N/A
- 52 Week Low
- TAC $5.94
- SRRK $6.76
- 52 Week High
- TAC $11.11
- SRRK $35.38
- Technical
- Relative Strength Index (RSI)
- TAC 58.68
- SRRK 61.20
- Support Level
- TAC $9.95
- SRRK $25.88
- Resistance Level
- TAC $10.36
- SRRK $28.30
- Average True Range (ATR)
- TAC 0.46
- SRRK 1.84
- MACD
- TAC 0.03
- SRRK -0.44
- Stochastic Oscillator
- TAC 81.61
- SRRK 79.96
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.